[引用][C] EE115 Clinical and Economic Impact of Glucagon-like Peptide-1 Agonists in Patients with Obstructive Sleep Apnea: An Exploratory Analysis
A Moreno-Calderón, HC Huerfano… - Value in …, 2024 - valueinhealthjournal.com
Objectives Assess the cost-utility of the glucagon-like peptide-1 agonists use in patients with
obstructive sleep apnea (OSA) who are unable or unwilling to use continuous positive …
obstructive sleep apnea (OSA) who are unable or unwilling to use continuous positive …
[HTML][HTML] Protocol: Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without …
Introduction Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often
occur concurrently, and untreated OSA may potentially amplify the high risk of …
occur concurrently, and untreated OSA may potentially amplify the high risk of …
Randomised, Controlled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without continuous positive airway …
Introduction Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often
occur concurrently, and untreated OSA may potentially amplify the high risk of …
occur concurrently, and untreated OSA may potentially amplify the high risk of …
8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep Apnea
K Cole, C Woodford, N Alpert, A Malhotra… - … HEALTH, COST, AND …, 2024 - atsjournals.org
RATIONALE: Obstructive sleep apnea (OSA) is often accompanied by comorbid obesity or
type 2 diabetes. Recently, glucagon-like peptide-1 receptor agonists (GLP-1s) have gained …
type 2 diabetes. Recently, glucagon-like peptide-1 receptor agonists (GLP-1s) have gained …
The case for early use of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome
R Sultana, F Sissoho, VP Kaushik, MA Raji - Life, 2022 - mdpi.com
Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes,
hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic …
hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic …
[PDF][PDF] Victoria S Sprung, Graham J Kemp, 4, 5 John PH Wilding, 2, 3 Valerie Adams, 5 Kieran Murphy, 5 Malcolm Burgess, 6 Stephen Emegbo, 7 Matthew Thomas, 7 …
SE Craig, DJ Cuthbertson - scholar.archive.org
Introduction Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often
occur concurrently, and untreated OSA may potentially amplify the high risk of …
occur concurrently, and untreated OSA may potentially amplify the high risk of …
S28 liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: Scale sleep apnoea trial
A Collier, A Blackman, G Foster, G Zammit… - 2014 - thorax.bmj.com
Aims/objectives This randomised, double-blind, parallel-group trial compared the effects of
liraglutide 3.0 mg to placebo, both as adjunct to diet and exercise, on obstructive sleep …
liraglutide 3.0 mg to placebo, both as adjunct to diet and exercise, on obstructive sleep …
Liraglutide-Based Weight Loss versus CPAP Therapy in improving Sleep Quality and Quality of Life of Patients with Obstructive Sleep Apnoea-an Explorative, Proof of …
C O'Donnell, A O'Mahony, M Traynor, R Gitau, S Ryan - 2023 - Eur Respiratory Soc
Obstructive sleep apnoea (OSA) is associated with reductions in sleep quality and quality of
life indices. Continuous positive airway pressure (CPAP) therapy improves quality of life, but …
life indices. Continuous positive airway pressure (CPAP) therapy improves quality of life, but …
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
A Blackman, GD Foster, G Zammit… - International journal of …, 2016 - nature.com
Background: Obesity is strongly associated with prevalence of obstructive sleep apnea
(OSA), and weight loss has been shown to reduce disease severity. Objective: To …
(OSA), and weight loss has been shown to reduce disease severity. Objective: To …
Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea
W Jiang, W Li, J Cheng, W Li, F Cheng - Sleep and Breathing, 2023 - Springer
Objectives To observe the efficacy and side effects of liraglutide in the treatment of type 2
diabetes mellitus (T2DM) patients with severe obstructive sleep apnea (OSA). Methods The …
diabetes mellitus (T2DM) patients with severe obstructive sleep apnea (OSA). Methods The …